The Vertex board expanded from 10 to 11 members on October 20, 2026, with the appointment of Daniel Brennan, the former chief financial officer of Boston Scientific. Brennan also joined Vertex Pharmaceuticals’ Audit and Finance Committee.
Key Takeaways
- Brennan’s appointment adds a director rather than replacing an existing board member.
- He led Boston Scientific’s finance function as CFO from January 2014 until June 2025.
- Vertex granted Brennan a $400,000 restricted stock unit award scheduled to vest in October 2027.
Table of Contents
- Vertex board appointment includes finance committee role
- A finance career spanning healthcare and technology
- Conclusion
Vertex board appointment includes finance committee role
Vertex’s October 20 Form 8-K confirms that Brennan’s board appointment and Audit and Finance Committee role took effect immediately. The expansion adds a former healthcare-company finance executive to the company’s governance structure.
Upon joining the board, Brennan received a $400,000 restricted stock unit award that will vest in October 2027. That amount represents an equity award, not a disclosed cash payment.
Vertex said there were no transactions involving the company and Brennan requiring disclosure under Item 404(a) of Regulation S-K. It also said no arrangement or understanding with any other person led to his appointment.
| Item | Details |
|---|---|
| Waters board | Director since November 2022. |
| Madrigal Pharmaceuticals board | Director since August 2025. |
| Education | B.S. in Finance and Investments and M.B.A. from Babson College. |
| Professional qualification | Certified public accountant. |
A finance career spanning healthcare and technology
Brennan served as Boston Scientific’s executive vice president and CFO from January 2014 until his retirement in June 2025. Before that, he was senior vice president and corporate controller from 2010 through 2013, following roles of increasing responsibility in the finance function from 1996 through 2009.
His experience also includes board positions at publicly traded companies in analytical instruments and biopharmaceuticals. He previously served on the board of Nuance until its acquisition by Microsoft in March 2022.
The appointment brings both executive finance experience and service on other public-company boards. Vertex’s disclosure concerns board membership and director compensation, rather than a change to its executive management team.
Conclusion
Brennan’s appointment is effective, with his committee assignment also in place. The next dated milestone disclosed for his director compensation is the restricted stock unit award’s vesting in October 2027.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
